SLN vs. SVRA, ZYME, AVBP, LYEL, MLYS, PHAR, ORIC, PHAT, STOK, and CALT
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Savara (SVRA), Zymeworks (ZYME), ArriVent BioPharma (AVBP), Lyell Immunopharma (LYEL), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
Savara currently has a consensus price target of $8.80, suggesting a potential upside of 96.43%. Silence Therapeutics has a consensus price target of $57.25, suggesting a potential upside of 148.91%. Given Savara's higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Savara.
87.9% of Savara shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 4.6% of Savara shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Silence Therapeutics has higher revenue and earnings than Savara. Silence Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
In the previous week, Savara had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 18 mentions for Savara and 10 mentions for Silence Therapeutics. Savara's average media sentiment score of 0.66 beat Silence Therapeutics' score of -0.04 indicating that Silence Therapeutics is being referred to more favorably in the news media.
Savara has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
Savara has a net margin of 0.00% compared to Savara's net margin of -131.44%. Silence Therapeutics' return on equity of -51.95% beat Savara's return on equity.
Savara received 264 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Silence Therapeutics an outperform vote while only 65.98% of users gave Savara an outperform vote.
Summary
Savara and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
